A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2006
11/23/2006	US20060264440 Pyrazoles and methods of making and using the same
11/23/2006	US20060264434 Chemokine receptor binding heterocyclic compounds
11/23/2006	US20060264432 Adenosine A1, A2a, and A2b receptor ligands; coupling the 2-mercapto-3,5-dicyano-4-aryl-6-aminopyridine to a substituted alkyl or alkenyl compound; antiischemic agents; cardiovascular disorders
11/23/2006	US20060264420 Tteating cell proliferation disease by modulation of kinesin and treatment of cancer
11/23/2006	US20060264397 Compositions and methods for targeting cancer cells
11/23/2006	US20060264388 Method for treating liver cancer by intrahepatic administration of nemorubicin
11/23/2006	US20060264378 Cxcr4 antagonist and use thereof
11/23/2006	US20060263881 Methods of expanding and selecting disease associated T-Cells
11/23/2006	US20060263852 Asp2
11/23/2006	US20060263827 Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances
11/23/2006	US20060263801 Methods of high-throughput screening for internalizing antibodies
11/23/2006	US20060263430 instrument for inducing cytokine and method of inducing cytokine
11/23/2006	US20060263383 Prognostic indicator
11/23/2006	US20060263381 Peptide epitopes common to antigens of the same multigene family
11/23/2006	US20060263376 Pharmaceutical composition comprising PIM-activated NKT cells, and use thereof in therapy
11/23/2006	US20060263373 Utilization of an aminopeptidase inhibitor
11/23/2006	US20060263371 Prognostic indicator
11/23/2006	US20060263370 Prognostic indicator
11/23/2006	US20060263369 Administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR); inhibiting angiogenesis
11/23/2006	US20060263366 Neoplasm specific antibodies and uses thereof
11/23/2006	US20060263362 Cancer metastasis inhibitor
11/23/2006	US20060263346 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
11/23/2006	US20060263333 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
11/23/2006	US20060263303 Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use
11/23/2006	US20060263294 Tumor targeting agents and uses thereof
11/23/2006	DE20221678U1 Preparation of an oxaliplatin active substance, useful in the treatment of cancer and comprising a very low content of oxalic acid
11/23/2006	DE20221674U1 Composition useful as a food or food supplement, and for treating e.g. tumors or osteoporosis, contains isoflavone, lignan and phytosterol
11/23/2006	CA2651450A1 Anti-cancer medication intended for immunotherapy treatments
11/23/2006	CA2616906A1 Molecular constructs suitable for targeted conjugates
11/23/2006	CA2609299A1 Raf inhibitor compounds and methods of use thereof
11/23/2006	CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006	CA2609069A1 Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
11/23/2006	CA2609067A1 An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating b cell neoplasm
11/23/2006	CA2609062A1 Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm
11/23/2006	CA2608974A1 Substituted 7,8-dihydro-1h-pyrimido[4,5-b][1,4]diazepin-4-amines are novel kinase inhibitors
11/23/2006	CA2608496A1 Imidazoquinolines as lipid kinase inhibitors
11/23/2006	CA2608473A1 Combination therapy
11/23/2006	CA2608463A1 Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
11/23/2006	CA2608447A1 Oxidative stress inhibitor
11/23/2006	CA2608442A1 Psk- i and its modulators for the treatment/diagnosis of cancer
11/23/2006	CA2608333A1 Pyrrolopyridine derivatives as protein kinase inhibitors
11/23/2006	CA2608009A1 Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
11/23/2006	CA2607299A1 Compounds and compositions as protein kinase inhibitors
11/23/2006	CA2606785A1 Fibroblast activation protein inhibitor compounds and methods
11/23/2006	CA2605272A1 Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
11/23/2006	CA2605050A1 Histone deacetylase inhibitors
11/23/2006	CA2604562A1 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
11/22/2006	EP1724351A2 Human Kallikrein-like genes
11/22/2006	EP1724350A1 Method and compositions for the diagnosis and treatment of cancer
11/22/2006	EP1724349A1 TIE Ligand Homologues
11/22/2006	EP1724270A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/22/2006	EP1724267A1 Pyrimidine derivative
11/22/2006	EP1724265A1 Anticancer agent
11/22/2006	EP1724264A1 Nitriles and medicinal compositions containing the same as the active ingredient
11/22/2006	EP1724263A1 Basic amine compound and use thereof
11/22/2006	EP1724262A1 1-(2h)-isoquinolone derivative
11/22/2006	EP1724258A1 Heteroarylphenylurea derivative
11/22/2006	EP1723970A1 Medicinal composition containing cxcr3 inhibitor
11/22/2006	EP1723963A2 Hapten-conjugated tumour cells
11/22/2006	EP1723954A1 Indazole derivatives for the treatment of cancer
11/22/2006	EP1723854A1 Beverage or drug containing bamboo extract as main ingredient
11/22/2006	EP1723415A1 Pdes as modifiers of the igfr pathway and methods of use
11/22/2006	EP1723166A2 Materials and methods relating to the treatment of glioblastomas
11/22/2006	EP1723165A1 Identification of n-alkylglycine trimers for induction of apoptosis
11/22/2006	EP1723152A1 Pyrrolobenzodiazepines
11/22/2006	EP1723151A2 Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
11/22/2006	EP1723148A2 Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
11/22/2006	EP1723146A1 Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
11/22/2006	EP1723139A1 Cell targeting conjugates
11/22/2006	EP1723138A1 Substituted benzimidazoles and their use for inducing apoptosis
11/22/2006	EP1723137A1 Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives
11/22/2006	EP1723131A1 Crystalline polymorphs of a cxc-chemokine receptor ligand
11/22/2006	EP1723125A1 Novel 1,2,4-benzotriazine-1,4-dioxides
11/22/2006	EP1723122A2 Dimeric small molecule potentiators of apoptosis
11/22/2006	EP1722857A2 Use of a compound having two gold(i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(i) atoms for the treatment of cancer
11/22/2006	EP1722823A2 Pharmaceutical composition
11/22/2006	EP1722817A1 Antineoplastic combinations of cci-779 and rituximab
11/22/2006	EP1722796A2 Tetracyclic lactam derivatives and uses thereof
11/22/2006	EP1722791A2 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
11/22/2006	EP1722779A1 Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents
11/22/2006	EP1722777A2 Use of beta-lapachone for the treatment of pancreatic cancer
11/22/2006	EP1722776A2 Use of beta-lapachone as a broad spectrum anti-cancer agent
11/22/2006	EP1722775A1 Use of beta-lapachone for treating hematologic tumors
11/22/2006	EP1572989B1 Gen 2.2 dendritic cell line
11/22/2006	EP1572715B1 Steroid compounds with anti-tumor activity
11/22/2006	EP1572673B1 Antioxidant from natural source
11/22/2006	EP1534265B1 Combination of an aromatase inhibitor with a bisphosphonate
11/22/2006	EP1530574B1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
11/22/2006	EP1499392B1 Method and agents for the prevention, inhibition, and therapy of cancers
11/22/2006	EP1474131B1 Use of anethole dithiolethione in lung cancer chemoprevention
11/22/2006	EP1467982B1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
11/22/2006	EP1458721B1 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use
11/22/2006	EP1458683B1 Heteroaryl-substituted aminocyclohexane derivatives
11/22/2006	EP1432402B1 Compositions for delivery of drug combinations
11/22/2006	EP1429756B1 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
11/22/2006	EP1423131B1 Calcium trifluoroacetate with cytotoxic activity
11/22/2006	EP1361899B1 Silicon implants comprising a radionucleotide for use in brachytherapy
11/22/2006	EP1360186B1 Carboline derivatives
11/22/2006	EP1317450B1 Pyrazole compounds useful as protein kinase inhibitors
11/22/2006	EP1315482B1 Water-dispersible encapsulated sterols

1 ... 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 ... 2211